Boston Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,910
| Closed | -$2.1M | – | 783 |
|
|
2025
Q3 | $2.1M | Buy |
15,910
+4,760
| +43% | +$571K | ﹤0.01% | 554 |
|
|
2025
Q2 | $1.18M | Hold |
11,150
| – | – | ﹤0.01% | 576 |
|
|
2025
Q1 | $1.38M | Buy |
11,150
+1,978
| +22% | +$258K | ﹤0.01% | 529 |
|
|
2024
Q4 | $1.13M | Hold |
9,172
| – | – | ﹤0.01% | 556 |
|
|
2024
Q3 | $1.02M | Buy |
9,172
+606
| +7% | +$66.4K | ﹤0.01% | 603 |
|
|
2024
Q2 | $914K | Sell |
8,566
-628
| -7% | -$69K | ﹤0.01% | 597 |
|
|
2024
Q1 | $1.11M | Sell |
9,194
-2,875
| -24% | -$352K | ﹤0.01% | 561 |
|
|
2023
Q4 | $1.48M | Buy |
12,069
+2,141
| +22% | +$267K | ﹤0.01% | 524 |
|
|
2023
Q3 | $1.29M | Buy |
9,928
+3,327
| +50% | +$443K | ﹤0.01% | 530 |
|
|
2023
Q2 | $818K | Hold |
6,601
| – | – | ﹤0.01% | 565 |
|
|
2023
Q1 | $966K | Buy |
6,601
+825
| +14% | +$122K | ﹤0.01% | 526 |
|
|
2022
Q4 | $920K | Buy |
5,776
+133
| +2% | +$19.5K | ﹤0.01% | 520 |
|
|
2022
Q3 | $752K | Buy |
5,643
+114
| +2% | +$17.3K | ﹤0.01% | 544 |
|
|
2022
Q2 | $862K | Sell |
5,529
-38,185
| -87% | -$5.88M | ﹤0.01% | 539 |
|
|
2022
Q1 | $6.81M | Sell |
43,714
-521,660
| -92% | -$75.7M | 0.01% | 384 |
|
|
2021
Q4 | $72M | Sell |
565,374
-4,435
| -0.8% | -$583K | 0.09% | 220 |
|
|
2021
Q3 | $74.2M | Buy |
569,809
+12,777
| +2% | +$1.93M | 0.09% | 225 |
|
|
2021
Q2 | $99M | Buy |
557,032
+8,053
| +1% | +$1.39M | 0.13% | 207 |
|
|
2021
Q1 | $90.2M | Sell |
548,979
-428,447
| -44% | -$70.5M | 0.12% | 213 |
|
|
2020
Q4 | $161M | Buy |
977,426
+2,824
| +0.3% | +$421K | 0.25% | 131 |
|
|
2020
Q3 | $139M | Sell |
974,602
-1,254
| -0.1% | -$155K | 0.25% | 129 |
|
|
2020
Q2 | $108M | Sell |
975,856
-301,745
| -24% | -$33.4M | 0.2% | 154 |
|
|
2020
Q1 | $127M | Sell |
1,277,601
-60,461
| -5% | -$7.82M | 0.25% | 118 |
|
|
2019
Q4 | $200M | Sell |
1,338,062
-26,820
| -2% | -$3.65M | 0.26% | 114 |
|
|
2019
Q3 | $175M | Buy |
1,364,882
+23,859
| +2% | +$3.2M | 0.24% | 121 |
|
|
2019
Q2 | $191M | Buy |
1,341,023
+35,360
| +3% | +$4.75M | 0.25% | 123 |
|
|
2019
Q1 | $187M | Sell |
1,305,663
-9,708
| -0.7% | -$1.27M | 0.25% | 124 |
|
|
2018
Q4 | $163M | Buy |
1,315,371
+198,306
| +18% | +$29.4M | 0.23% | 125 |
|
|
2018
Q3 | $188M | Buy |
1,117,065
+27,409
| +3% | +$4.71M | 0.22% | 130 |
|
|
2018
Q2 | $188M | Buy |
1,089,656
+18,821
| +2% | +$3.08M | 0.23% | 134 |
|
|
2018
Q1 | $162M | Sell |
1,070,835
-128,353
| -11% | -$18.8M | 0.2% | 145 |
|
|
2017
Q4 | $161M | Buy |
+1,199,188
| New | +$166M | 0.19% | 144 |
|
Other funds holding JAZZ
EC
Boston Partners's JAZZ Position: Q4 2025 in Review
Boston Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 15,910 shares — an estimated $2.1M sold.
Boston Partners first reported a position in JAZZ in Q4 2017 and held it in 32 quarters. The position peaked at $200M in Q4 2019. 574 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.
- Boston Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Boston Partners sold 15,910 Jazz Pharmaceuticals shares in Q4 2025, an estimated $2.1M.
- Boston Partners first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 32 quarters.
- Boston Partners's Jazz Pharmaceuticals position peaked at $200M in Q4 2019.
- 574 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.
Based on Boston Partners's 13F filing for Q4 2025, filed 13 Feb 2026.